Callan JMB Reports Full Year 2025 Financial Results and Provides Business Update

Core Insights - Callan JMB Inc. is focusing on strengthening its government relationships at both state and federal levels to support onshoring initiatives and enhance its core emergency preparedness operations [1][2] - The company is actively pursuing growth initiatives in healthcare and food manufacturing sectors, aiming to expand its pharmaceutical logistics and specialty distribution operations [2] Business Highlights - Callan JMB signed a manufacturing oversight and commercialization agreement with Attune Biotech Inc. to oversee manufacturing and quality assurance for its therapeutic pipeline [3] - A joint venture was established with Revival Health to integrate logistics and data infrastructure for U.S.-based manufacturing [3] - The company launched Callan JMB Services (India) Private Limited, planning a temperature-controlled warehouse in Pune for pharmaceutical storage [3] - An emergency preparedness contract with the City of Chicago was extended through June 2026, increasing total contract value to $9.1 million [3] Financial Highlights - Revenues for the year ended December 31, 2025, were $5.7 million, a decrease from $6.6 million in 2024, attributed to reduced demand for emergency preparedness services [8] - Cost of revenues decreased to $3.6 million from $4 million in 2024, primarily due to the decline in revenue [8] - SG&A expenses rose to $8.6 million from $4.8 million in 2024, driven by increased professional fees related to the company's IPO [8] - The net loss for the year was $7.97 million, compared to a loss of $2.29 million in 2024, with a net loss per share of $1.82 [10]